This activity is supported by an educational grant from Actelion Pharmaceuticals US, Inc.
page 1 of 5
Please click on Next tab to advance through activity.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2019 Healio All Rights Reserved.
Activity Release Date: 12/21/2018; Activity Expiration Date: 12/21/2019
Time to Complete: 45 minutes
0.75 / AMA PRA Category 1 Credit™
The therapeutic goals for Pulmonary Arterial Hypertension are to improve the hemodynamic parameters, delay disease progression, improving quality of life and exercise tolerance, and minimizing mortality risks. This activity will focus on several important aspects of PAH management including a review of the predictors of disease progression and clinical outcomes of PAH; the current data on the use of NYHA functional class as a predictor of future survival and disease progression; a discussion of the clinical trial data on existing and emerging therapeutics for the management of PAH; and a review of effective strategies to tailor therapeutic regimens and improve clinical outcomes in patients with PAH.
This activity is intended for cardiologists, physicians and other healthcare professionals who are involved in the management of patients with pulmonary arterial hypertension.
Upon completion of the educational activity, participants should be able to:
AKH Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points and 0 patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.
Criteria for Success
Statements of credit will be awarded based on completing the pre-test, participant watching full video, scoring at least 70% on the post test, and completing an activity evaluation. A statement of credit will be available upon completion of an online evaluation/claimed credit form. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this CE activity, please contact AKH Inc. at email@example.com.
This activity is supported by an educational grant from Actelion Pharmaceuticals US, Inc.
About our Faculty
Barry H. Greenberg, MD
Distinguished Professor of Medicine
Director, Advanced Heart Failure Treatment Program
UCSD Medical Center
San Diego, CA
Barry H. Greenberg, MD, is Distinguished Professor of Medicine and Director of the Advanced Heart Failure Treatment Program at the University of California, San Diego (UCSD). He earned a medical degree from the State University of New York Upstate Medical University College of Medicine in Syracuse and completed his internship at George Washington University Hospital and residency in internal medicine at Yale-New Haven Hospital. Following research training at the Lipid Metabolism Branch of the National Heart, Lung, and Blood Institute in Bethesda, Maryland and the Cardiovascular Research Institute of the University of California, San Francisco (UCSF), he completed a fellowship in cardiology at UCSF. He then joined the faculty of Oregon Health Sciences University School of Medicine. Prior to arriving at UCSD, he was visiting professor in residence at the Royal Postgraduate Medical School in London, England and at the Laboratoire de Médicine Expérimentale of the Collège de France in Paris.
Dr. Greenberg’s clinical research focuses on understanding mechanisms of cardiac dysfunction and developing new heart failure therapies. He has served on the executive steering committees of numerous international multicenter heart failure trials including most recently RELAX-AHF2, RELAX-AHF Asia, COMMANDER-HF (co-chair) and DREAM-HF (co-chair). In addition, Dr. Greenberg directs a basic science laboratory that studies the molecular basis of cardiac remodeling, myocardial fibrosis and the development of novel therapies. He has published extensively in medical journals throughout his career.
Dr. Greenberg is co-editor of Congestive Heart Failure: Pathophysiology, Diagnosis, and Comprehensive Approach to
Management, the first comprehensive text in this field, now in its 3rd edition and is editor of Myocardial Remodeling:
Mechanisms and Treatment, published in 2006 and Management of Heart Failure published in 2010. He served as Associate Editor for the Journal of the American College of Cardiology (JACC) from 2002-2014 and is a member of the editorial boards of several cardiology and subspecialty journals including JACC: Heart Failure and the European Journal of Heart Failure.
Dr. Greenberg is a founding member and past President of the Heart Failure Society of America (HFSA). He chaired the
initial HFSA Heart Failure Board Review Course and he also has served as Chair for numerous HFSA Committees (including Education, Advocacy, Nominating, and Corporate Affairs) and for the Strategic Development initiative in 2010.
Dr. Greenberg has been recognized for many years as being one of the “Best Doctors in America” and “Best Doctors in
San Diego.” Dr. Greenberg received the HFSA’s Lifetime Achievement Award in 2017.
Dr. Greenberg has disclosed the following relevant financial relationships:
Consultant - Bayer, Janssen, Mesoblas, Novartis, Zensun
Speakers Bureau - Novartis, Otsuka
Margaret V. Clark, MSc, RN, RRT - NPS, CMPP, Medical Writer/Interviewer: has disclosed no relevant financial relationships.
Dorothy Caputo, MA, BSN, RN, Lead Nurse Planner/Reviewer: has disclosed no relevant financial relationships.
Patricia Brignoni, AKH Director of Operations/Reviewer: has disclosed no relevant financial relationships.
Steve Eckert, AKH President & CEO, Planner/Reviewer: has disclosed no relevant financial relationships.
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH planners and reviewers have no relevant financial relationships to disclose.
Continuing Medical Education and Continuing Education
When you register for a Continuing Medical Education (CME) or a Continuing Education (CE) activity through one of our Web sites, we collect certain personally identifiable information from you such as your name, email address and mailing address. If you are a pharmacist and wish to receive CE credit, you are also required to provide your NAPB # and month and day of birth. For more information about NABP and CPE Monitor click here. In addition to personally identifiable information, we collect aggregated non-personally identifiable information about the activities undertaken by our users. We use the information that we collect through CME/CE activities in several ways:
HARDWARE AND SOFTWARE REQUIREMENTS
• A computer with an internet connection
• Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
• Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required